Rocket Pharmaceuticals, Inc. Accounts Payable and Accrued Liabilities, Current
Rocket Pharmaceuticals, Inc. (RCKT) had Accounts Payable and Accrued Liabilities, Current of $28.34 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Payable and Accrued Liabilities, Current $28.34M.
- 2026-03-31: Accounts Payable and Accrued Liabilities, Current $21.54M.
- 2025-12-31: Accounts Payable and Accrued Liabilities, Current $27.29M.
- 2025-09-30: Accounts Payable and Accrued Liabilities, Current $28.26M.
| Period end | Accounts Payable and Accrued Liabilities, Current | Accounts Payable and Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $28.34M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $21.54M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $27.29M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $28.26M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $40.51M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $32.44M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $37.83M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $37.13M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $34.73M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $30.09M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $45.79M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $30.62M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $31.35M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $28.61M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $36.66M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $27.82M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $21.84M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $20.03M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $19.61M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $22.01M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $17.88M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $33.17M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $25.47M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $24.83M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $18.25M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $18.82M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $17.35M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $21.25M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $14.17M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $19.68M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $15.37M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $9.77M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $8.29M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $4.76M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $4.52M 10-K · filed 2019-03-08 | $2.06M 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |